贞术调脂胶囊治疗高脂血症的效果

Abstract
Figure/Table
References (20)
Related Citation (15)

Download: PDF (648 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the effect of Zhenzhu Tiaozhi Capsules for the treatment of hyperlipidemia. Methods A total of 80 patients with hyperlipidemia admitted to the First Affiliated Hospital of Guangdong Pharmaceutical University from May 2019 to May 2021 were selected as the research subjects. According to random number table method, they were divided into experimental group (n=40) and control group (n=40). The control group was given conventional drug treatment, and the experimental group was given Zhenzhu Tiaozhi Capsules treatment on the basis of the control group, and all were treated for 12 weeks. The blood lipid level, traditional Chinese medicine (TCM) syndrome efficacy and adverse events of the two groups were compared. Results There were no significant differences in the levels of serum total cholesterol (TC), triglyceride (TG), low density lipoprotein cholesterol (LDL-C) and high density lipoprotein cholesterol (HDL-C) between the two groups before treatment (P>0.05). After 4 and 12 weeks of treatment, the levels of serum TC, TG, LDL-C in the two groups were lower than those before treatment, while HDL-C levels were higher than those before treatment, and the levels of serum TC, TG and LDL-C in the experimental group were lower than those in the control group, and the level of HDL-C was higher than that in the control group, the differences were statistically significant (P<0.05). The total effective rate of TCM syndrome in the experimental group was higher than that in the control group, the difference was statistically significant (P<0.05). There was no significant difference in the total incidence of adverse events between the two groups (P>0.05). Conclusion Zhenzhu Tiaozhi Capsules has a significant effect on hyperlipidemia, which can improve blood lipid level and TCM syndrome of patients more effectively, and has a high safety.

Key words： Zhenzhu Tiaozhi Capsules Hyperlipidemia Blood lipid Traditional Chinese medicine syndrome score Adverse event

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	FAN Suiqiang
	MENG Chunxiang
	ZHANG Kaina
	JIN Yinghua

Cite this article:

FAN Suiqiang,MENG Chunxiang,ZHANG Kaina, et al. Effect of Zhenzhu Tiaozhi Capsules on hyperlipidemia[J]. 中国当代医药, 2022, 29(4): 16-19.

URL:

https://www.dangdaiyiyao.com/EN/ OR https://www.dangdaiyiyao.com/EN/Y2022/V29/I4/16

[1]	李文毅，周春阳.高脂血症与动脉粥样硬化和脂代谢研究进展[J].中国药理学与毒理学杂志，2019，33（10）：811.
[2]	郑建国，郑雪娟.高血压和血脂异常患者脑血流动力学指标变化的研究[J].中国卫生标准管理，2021，12（5）：98-100.
[3]	谷新伟.老年急性心肌梗死危险因素调查分析[J].应用预防医学，2020，26（5）：412-413，416.
[4]	李苏宁，张林峰，王馨，等.2012-2015年我国年龄≥35岁人群血脂异常状况调查[J].中华高血压杂志，2020，28（10）：1000.
[5]	诸骏仁，高润霖，赵水平，等.中国成人血脂异常防治指南（2016年修订版）[J].中华健康管理学杂志，2017，11（1）：7-28.
[6]	中华人民共和国卫生部.中药新药临床研究指导原则[M].北京：中国中医药科技出版社，2002：181-182.
[7]	武恩平，刘奕廷，李建彬.2018年郑州市18岁及以上居民血脂异常流行特征及影响因素分析[J].中国慢性病预防与控制，2019，27（9）：679-683.
[8]	李文毅，周春阳.高脂血症与动脉粥样硬化和脂代谢研究进展[J].中国药理学与毒理学杂志，2019，33（10）：811.
[9]	舒筠然，李俊琪，刘琼.非酒精性脂肪性肝病的流行病学和危险因素分析[J].临床肝胆病杂志，2019，35（9）：2085-2090.
[10]	胡俊贤，龚明惠，陈冬苗，等.阿托伐他汀钙与瑞舒伐他汀钙治疗高脂血症的疗效及安全性差异分析[J].海峡药学，2020，32（3）：151-152.
[11]	童早英.匹伐他汀钙片联合阿司匹林治疗冠心病高脂血症的临床效果[J].中国当代医药，2021，28（3）：83-86.
[12]	刘晶晶，贾连群，吕美君，等.高脂血症中西医结合研究进展[J].中华中医药学刊，2017，35（4）：815-818.
[13]	王臬，陈平，洪钰芳，等.中医治疗高脂血症研究进展[J].实用中医药杂志，2019，35（2）：247-249.
[14]	许宏磊，胡俊涛，兰丙欣，等.蒲参胶囊联合匹伐他汀治疗高脂血症的临床研究[J].现代药物与临床，2019，34（10）：2926-2930.
[15]	张颖，王忠良，陈思光，等.调脂消斑合剂联合西药治疗冠心病高脂血症患者的效果及对UA、Hcy的影响[J].中国现代医生，2020，58（12）：42-46.
[16]	甄毅锋，王洪云，饶晓平，等.复方贞术调脂胶囊对非酒精性脂肪肝的疗效及安全性观察[J].按摩与康复医学，2018，9（17）：29-30.
[17]	Guo J.Research Progress on Prevention and Treatment of Glucolipid Metabolic Disease with Integrated Traditional Chinese and Western Medicine[J].Chin J Integr Med，2017， 23（6）：403-409.
[18]	叶艮英，丁少波，梁淑贞，等.丹参多酚酸盐联合阿托伐他汀钙治疗慢性肾脏病合并高脂血症的疗效观察[J].中国药物与临床，2019，19（19）：3388-3390.
[19]	张仁丹，黎土娣，王加伟，等.复方贞术调脂胶囊对兔腹主动脉再狭窄模型血脂及炎症因子的影响[J].中国病理生理杂志，2018，34（2）：270-275.
[20]	吕水利，高晓博，王鹏，等.他汀类药物的多效性研究进展[J].人民军医，2020，63（3）：289-292.